Omeros | OMER - Selling And Administration Expenses

Stock Price
12.19
Daily Change
-1.10 -8.25%
Monthly
-2.83%
Yearly
279.00%
Q2 Forecast
13.84

Omeros reported $11.32M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
Adma Biologics USD 20.19M 2.86M Dec/2025
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Cytokinetics USD 104.9M 13.17M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Immunic USD 3.45M 451K Dec/2025
Insmed USD 247.26M 34.78M Mar/2026
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
MacroGenics USD 7.94M 1.96M Dec/2025
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 83.88M 7.99M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Rockwell Medical USD 4.04M 330K Jun/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
United Therapeutics USD 156.6M 34M Mar/2026
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026
Xoma USD 11M 2.54M Jun/2024